银屑病患者的系统性银屑病治疗与合并症：潜在风险与益处综述
Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits.
作者信息
Mikhaylov Daniela, Hashim Peter W, Nektalova Tatyana, Goldenberg Gary
机构信息
Ms. Mikhaylov and Drs. Hashim, Nektalova, and Goldenberg are with the Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York, New York.
Dr. Goldenberg is also with Goldenberg Dermatology, PC, in New York, New York.
出版信息
J Clin Aesthet Dermatol. 2019 Jun;12(6):46-54. Epub 2019 Jun 1.
Abstract
Psoriasis is an inflammatory skin disease that is associated with many comorbidities. Several psoriasis treatments approved by the United States Food and Drug Administration have been shown to have beneficial effects on these comorbidities, while others might lead to an exacerbation of these conditions. In this article, we review studies of psoriasis treatments and their level of evidence for use in co-occurring diseases. An awareness of the multifaceted effects of certain psoriasis medications can enable physicians to provide more personalized treatment to their most complicated patients.
摘要
银屑病是一种与多种合并症相关的炎症性皮肤病。美国食品药品监督管理局批准的几种银屑病治疗方法已被证明对这些合并症有有益效果，而其他一些治疗方法可能会导致这些病情加重。在本文中，我们回顾了银屑病治疗方法及其在并发疾病中应用的证据水平的研究。了解某些银屑病药物的多方面影响可以使医生为最复杂的患者提供更个性化的治疗。
相似文献
1
Systemic Psoriasis Therapies and Comorbid Disease in Patients with Psoriasis: A Review of Potential Risks and Benefits.银屑病患者的系统性银屑病治疗与合并症：潜在风险与益处综述
J Clin Aesthet Dermatol. 2019 Jun;12(6):46-54. Epub 2019 Jun 1.
2
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.炎症性肠病患者的银屑病管理：来自全国银屑病基金会医学委员会。
J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043.
3
Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents.银屑病：哪种疗法适合哪种患者：银屑病合并症和首选的系统药物。
J Am Acad Dermatol. 2019 Jan;80(1):27-40. doi: 10.1016/j.jaad.2018.06.057. Epub 2018 Jul 11.
4
Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review.聚焦于并发银屑病和炎症性肠病的治疗武器库：系统评价。
J Dermatolog Treat. 2022 May;33(3):1279-1286. doi: 10.1080/09546634.2020.1836313. Epub 2020 Oct 22.
5
The Psoriasis Decision Tree.银屑病决策树
J Clin Aesthet Dermatol. 2021 Apr;14(4):14-22. Epub 2021 Apr 1.
6
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.银屑病的病理生理学、临床表现和治疗：综述。
JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006.
7
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis.靶向 DMARDs 在诱导治疗中治疗活动性银屑病关节炎的疗效和安全性比较：系统评价和网络荟萃分析。
Semin Arthritis Rheum. 2019 Dec;49(3):381-388. doi: 10.1016/j.semarthrit.2019.06.001. Epub 2019 Jun 10.
8
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments.甲银屑病：当前可用全身治疗方法的最新综述
Clin Cosmet Investig Dermatol. 2023 Jul 24;16:1899-1932. doi: 10.2147/CCID.S417679. eCollection 2023.
9
Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis.接受全身性药物治疗银屑病的患者发生严重感染的风险
JAMA Dermatol. 2019 Oct 1;155(10):1142-1152. doi: 10.1001/jamadermatol.2019.1121.
10
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations.欧洲皮肤性病学会寻常型银屑病系统治疗指南 - 第1部分：治疗与监测建议
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):2461-2498. doi: 10.1111/jdv.16915.
引用本文的文献
1
Placebo-Controlled Trials in the Management of Crohn's Disease: An Umbrella Review of Meta-Analyses.克罗恩病管理中的安慰剂对照试验：荟萃分析的伞状综述
Med Sci (Basel). 2025 Jan 29;13(1):12. doi: 10.3390/medsci13010012.
2
Sprayable inflammasome-inhibiting lipid nanorods in a polymeric scaffold for psoriasis therapy.用于治疗银屑病的聚合物支架中的可喷涂炎性体抑制脂质纳米棒。
Nat Commun. 2024 Oct 19;15(1):9035. doi: 10.1038/s41467-024-53396-x.
3
Blue light emitting graphene quantum dots/ Rhodamine B doped gold nanostars for ratiometric detection of methotrexate.用于甲氨蝶呤比率检测的蓝光发射石墨烯量子点/罗丹明B掺杂金纳米星
Heliyon. 2024 Sep 13;10(18):e37914. doi: 10.1016/j.heliyon.2024.e37914. eCollection 2024 Sep 30.
4
Molecular mechanisms underlying methotrexate-induced intestinal injury and protective strategies.甲氨蝶呤诱导的肠道损伤的分子机制及保护策略。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8165-8188. doi: 10.1007/s00210-024-03164-x. Epub 2024 Jun 1.
5
Advancements in the Study of Biologic Agents in Comorbidities of Psoriasis: A Literature Review.银屑病合并症生物制剂研究进展：文献综述
Clin Cosmet Investig Dermatol. 2023 Dec 4;16:3487-3495. doi: 10.2147/CCID.S439110. eCollection 2023.
6
Curcumin Alleviates Epidermal Psoriasis-Like Dermatitis and IL-6/STAT3 Pathway of Mice.姜黄素减轻小鼠表皮银屑病样皮炎及IL-6/STAT3信号通路
Clin Cosmet Investig Dermatol. 2023 Sep 1;16:2399-2408. doi: 10.2147/CCID.S423922. eCollection 2023.
7
Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus.甲氨蝶呤治疗皮肤病的真实世界经验：一项意大利德尔菲共识。
Dermatol Ther (Heidelb). 2023 Jun;13(6):1219-1241. doi: 10.1007/s13555-023-00930-2. Epub 2023 May 21.
8
Therapy of PsO in Special Subsets of Patients.特殊患者亚组中银屑病的治疗。
Biomedicines. 2022 Nov 10;10(11):2879. doi: 10.3390/biomedicines10112879.
9
Real-World Effects of Biologics on Renal Function in Psoriatic Patients: A Retrospective Study.真实世界中生物制剂对银屑病患者肾功能的影响：一项回顾性研究。
BioDrugs. 2022 Sep;36(5):657-666. doi: 10.1007/s40259-022-00547-5. Epub 2022 Aug 22.
10
Comparative Study on the Clinical Efficacy and Safety of Acitretin and MTX in the Treatment of Pustular Psoriasis by TLR7/MyD88/CXCL16 Pathway.阿维A与甲氨蝶呤通过TLR7/MyD88/CXCL16通路治疗脓疱型银屑病的临床疗效及安全性对比研究
Appl Bionics Biomech. 2022 Mar 18;2022:9640326. doi: 10.1155/2022/9640326. eCollection 2022.
本文引用的文献
1
Tildrakizumab: First Global Approval.替度鲁单抗：全球首次获批。
Drugs. 2018 Jun;78(8):845-849. doi: 10.1007/s40265-018-0917-3.
2
Emerging therapies in psoriasis: a systematic review.银屑病的新兴疗法：一项系统综述。
Cutis. 2018 Mar;101(3S):5-9.
3
Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis.银屑病与慢性肾脏病及终末期肾病发病风险：一项系统评价与荟萃分析
Int Urol Nephrol. 2018 Jul;50(7):1277-1283. doi: 10.1007/s11255-018-1868-z. Epub 2018 Apr 11.
4
Risk Factors Affecting Adverse Effects of Cyclosporine A in a Real-World Psoriasis Treatment.影响环孢素A在实际银屑病治疗中不良反应的危险因素
Ann Dermatol. 2018 Apr;30(2):143-149. doi: 10.5021/ad.2018.30.2.143. Epub 2018 Feb 21.
5
The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report.皮下注射甲氨蝶呤对银屑病患者代谢综合征标志物的影响——初步报告
Postepy Dermatol Alergol. 2018 Feb;35(1):53-59. doi: 10.5114/ada.2017.71358. Epub 2018 Feb 20.
6
Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.依奇珠单抗治疗对中重度斑块型银屑病患者的心血管参数无显著影响：UNCOVER-1、UNCOVER-2 和 UNCOVER-3 研究结果。
J Am Acad Dermatol. 2018 Jul;79(1):104-109.e8. doi: 10.1016/j.jaad.2018.02.074. Epub 2018 Mar 13.
7
Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.炎症性肠病患者的银屑病管理：来自全国银屑病基金会医学委员会。
J Am Acad Dermatol. 2018 Feb;78(2):383-394. doi: 10.1016/j.jaad.2017.06.043.
8
Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment.银屑病与心血管合并症：关注严重血管事件、心血管风险因素及治疗影响。
Int J Mol Sci. 2017 Oct 21;18(10):2211. doi: 10.3390/ijms18102211.
9
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.巴柳氮钠治疗过程中的精神不良事件：银屑病临床试验分析。
J Am Acad Dermatol. 2018 Jan;78(1):81-89.e5. doi: 10.1016/j.jaad.2017.08.024. Epub 2017 Oct 3.
10
Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab).接受白细胞介素-12/23 阻断（乌司奴单抗）治疗的银屑病患者的代谢参数。
J Dermatol. 2018 Mar;45(3):309-313. doi: 10.1111/1346-8138.14079. Epub 2017 Oct 5.
Zotero 插件